Bostwick Labs plans IPO

Of interest, CNN reports: Bostwick Labs plans IPO.

"Bostwick focuses on the urologic pathology market segment, including prostate cancer biopsies, and the gynecologic pathology segment, including cervical cancer screenings.

"In its prospectus, Bostwick said its business model was developed by founder and Chief Executive David Bostwick, a former professor of pathology and urology at the Mayo Clinic. The CEO will continue to be the company's controlling shareholder after the IPO.

"Bostwick, which was founded in 1999, has five laboratories in Virginia, Arizona, New York, Florida, and London. The company has more than 750 employees. In 2007, Bostwick analyzed about 291,000 cases, compared with about 159,000 in 2006, an increase of 83 percent.

Seems like one use of the IPO proceeds could be implementation of digital pathology?